Safety, tolerability, and pharmacokinetics of fluoropezil (DC20), a novel acetylcholinesterase inhibitor: A phase I study in healthy young and elderly Chinese subjects.

Bibliographic Details
Title: Safety, tolerability, and pharmacokinetics of fluoropezil (DC20), a novel acetylcholinesterase inhibitor: A phase I study in healthy young and elderly Chinese subjects.
Authors: Qian H; Drug Clinical Trial Center, Shanghai Xuhui Central Hospital/Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China.; Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs, Shanghai, China., Yu C; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China., Zhu H; Drug Clinical Trial Center, Shanghai Xuhui Central Hospital/Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China.; Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs, Shanghai, China., Ding Q; Drug Clinical Trial Center, Shanghai Xuhui Central Hospital/Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China.; Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs, Shanghai, China., Cai Y; Drug Clinical Trial Center, Shanghai Xuhui Central Hospital/Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China.; Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs, Shanghai, China., Jing J; Jiangsu Kanion Pharmaceutical Co., Ltd, Lianyungang, China., Xu X; Shanghai Kerlin Biomedical Technology Co., Ltd, Shanghai, China., Guo R; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China., Zhang H; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China., Liu H; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China., Chen X; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China., Liu Y; Drug Clinical Trial Center, Shanghai Xuhui Central Hospital/Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China.; Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs, Shanghai, China.
Source: Clinical and translational science [Clin Transl Sci] 2023 May; Vol. 16 (5), pp. 810-822. Date of Electronic Publication: 2023 Feb 26.
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1752-8062 (Electronic) Linking ISSN: 17528054 NLM ISO Abbreviation: Clin Transl Sci Subsets: MEDLINE
Database: MEDLINE Complete
Full text is not displayed to guests.
Description
ISSN:1752-8062
DOI:10.1111/cts.13490